Pfizer (NYSE:PFE) Price Target Raised to $30.00

Pfizer (NYSE:PFE) had its price target raised by equities researchers at UBS Group from $27.00 to $30.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group‘s price objective indicates a potential downside of 2.58% from the stock’s previous close.

Other analysts also recently issued research reports about the company. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Citigroup raised their target price on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday. Cantor Fitzgerald lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $29.29.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.79 during mid-day trading on Wednesday, reaching $30.79. 50,576,436 shares of the company traded hands, compared to its average volume of 39,838,277. Pfizer has a fifty-two week low of $23.62 and a fifty-two week high of $31.06. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market cap of $175.52 billion, a PE ratio of 40.52, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. The stock has a fifty day simple moving average of $28.64 and a 200-day simple moving average of $26.84.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.87 earnings per share. Equities research analysts anticipate that Pfizer will post 2.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently modified their holdings of the stock. Retirement Wealth Solutions LLC boosted its holdings in shares of Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 509 shares during the period. Keb Asset Management LLC purchased a new position in shares of Pfizer in the second quarter worth approximately $26,000. Field & Main Bank acquired a new stake in shares of Pfizer during the second quarter valued at approximately $27,000. Bullseye Investment Management LLC acquired a new stake in shares of Pfizer during the second quarter valued at approximately $28,000. Finally, Timbuktu Capital Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat Q3 estimates, reporting adjusted earnings of $0.87 per share and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS guidance to $2.95–$3.05, citing solid performance and cost-saving progress. Pfizer Q3 results and guidance
• Positive Sentiment: Growth beyond COVID is gaining traction: non-COVID products grew 7% operationally, while launched and acquired products rose 32%. Eliquis and oncology medicines were among the growth drivers, helping offset weaker pandemic-product sales. Long-term investor takeaways
• Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling confidence in further potential gains. Scotiabank rating
• Neutral Sentiment: Analyst views remain mixed: Citigroup raised its target to $30 but kept a “neutral” rating, while RBC’s higher $28 target still sits below the current share price. This suggests some caution despite recent target increases. Citigroup rating
• Neutral Sentiment: CEO Albert Bourla is pursuing a larger role in the obesity-drug market, an opportunity that could support longer-term growth, but its commercial impact remains to be demonstrated. Pfizer’s obesity-market ambitions
• Negative Sentiment: COVID-product sales continued to fall, and overall quarterly revenue was nearly flat year over year. The ongoing decline keeps pressure on Pfizer to prove its newer portfolio can replace pandemic-era revenue and sustain growth. Reuters report on Pfizer’s outlook

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.